ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 109 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,556,283 | -44.5% | 3,117,944 | -0.3% | 0.12% | -18.0% |
| Q2 2023 | $29,807,715 | -13.6% | 3,127,777 | -0.2% | 0.15% | -33.0% |
| Q1 2023 | $34,490,643 | +16.2% | 3,135,513 | +56.3% | 0.22% | -5.5% |
| Q4 2022 | $29,685,500 | +18.6% | 2,005,777 | +53.2% | 0.24% | +49.1% |
| Q3 2022 | $25,020,000 | -16.5% | 1,309,268 | -6.9% | 0.16% | -9.7% |
| Q2 2022 | $29,958,000 | -12.8% | 1,405,796 | -21.2% | 0.18% | +13.5% |
| Q1 2022 | $34,360,000 | -7.1% | 1,784,005 | 0.0% | 0.16% | +11.5% |
| Q4 2021 | $37,000,000 | -0.0% | 1,784,005 | +15.2% | 0.14% | -7.9% |
| Q3 2021 | $37,003,000 | -19.4% | 1,548,901 | -7.9% | 0.15% | -24.1% |
| Q2 2021 | $45,917,000 | +1.9% | 1,682,543 | +8.0% | 0.20% | -28.7% |
| Q1 2021 | $45,060,000 | +106.7% | 1,557,543 | +101.0% | 0.28% | +111.4% |
| Q4 2020 | $21,801,000 | – | 775,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |